All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

glipizide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihyperglycaemics	1301	29094-61-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: glypidizine glidiazinamide K 4024 K-4024 K4024 glipizide dipazide glibenese glipizid glucotrol glucozide glupizide glydiazinamide melizide napizide sucrazide	An oral hypoglycemic agent which is rapidly absorbed and completely metabolized. Molecular weight: 445.54 Formula: C21H27N5O4S CLOGP: 2.60 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 130.15 ALOGS: -4.43 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	4.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.96 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.56 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.30 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,MAPK7,PDK1,PDK2,PIK3CB,PRKDC,TEK	15
kinase-selectivity-class	GRK2	1
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	18.664		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
rat-kpuu-brain	Rat brain Kpuu	0.013	%	High	1

Approvals:

Date	Agency	Company	Orphan
May 8, 1984	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood glucose increased	800.48	12.22	502	38408	94744	90494793
Hypoglycaemia	563.61	12.22	359	38551	69489	90520048
Cardiac failure congestive	396.99	12.22	333	38577	98361	90491176
Blood glucose decreased	326.71	12.22	172	38738	23257	90566280
Myocardial infarction	244.54	12.22	263	38647	105709	90483828
Coronary artery disease	232.39	12.22	157	38753	33466	90556071
Diabetes mellitus inadequate control	168.05	12.22	103	38807	18581	90570956
Cerebrovascular accident	156.48	12.22	227	38683	123306	90466231
Lactic acidosis	133.82	12.22	135	38775	50328	90539209
Glycosylated haemoglobin increased	120.42	12.22	78	38832	15484	90574053
Product residue present	120.24	12.22	51	38859	4240	90585297
Infusion related reaction	119.93	12.22	18	38892	416762	90172775
Contraindicated product administered	109.83	12.22	7	38903	320132	90269405
Systemic lupus erythematosus	103.25	12.22	16	38894	361880	90227657
Synovitis	102.69	12.22	11	38899	329741	90259796
Glossodynia	102.11	12.22	10	38900	321769	90267768
Pericarditis	98.68	12.22	4	38906	270147	90319390
Blood glucose fluctuation	90.37	12.22	44	38866	5039	90584498
Exposure during pregnancy	82.39	12.22	5	38905	238405	90351132
Drug intolerance	82.12	12.22	45	38865	447546	90141991
Hypoglycaemic coma	81.99	12.22	35	38875	2955	90586582
Renal failure	80.06	12.22	175	38735	130832	90458705
Product complaint	79.13	12.22	57	38853	13443	90576094
Pancreatitis	77.92	12.22	121	38789	69705	90519832
Helicobacter infection	77.66	12.22	5	38905	226845	90362692
Off label use	76.61	12.22	232	38678	1102020	89487517
Lower respiratory tract infection	76.41	12.22	9	38901	250650	90338887
Wound	74.69	12.22	19	38891	302961	90286576
General physical health deterioration	73.89	12.22	30	38880	355085	90234452
Hyperglycaemia	70.88	12.22	98	38812	50872	90538665
Arthropathy	69.85	12.22	35	38875	366207	90223330
Rheumatoid arthritis	67.15	12.22	36	38874	362578	90226959
Acute kidney injury	66.42	12.22	293	38617	320094	90269443
Treatment failure	66.00	12.22	24	38886	303904	90285633
Blood glucose abnormal	64.78	12.22	44	38866	9448	90580089
Dehydration	63.74	12.22	206	38704	194241	90395296
Euglycaemic diabetic ketoacidosis	63.05	12.22	37	38873	6164	90583373
Joint swelling	63.05	12.22	74	38836	503226	90086311
Mental status changes	62.27	12.22	86	38824	44593	90544944
C-reactive protein increased	62.07	12.22	4	38906	181385	90408152
Diabetes mellitus	60.94	12.22	104	38806	64771	90524766
Irritable bowel syndrome	57.28	12.22	10	38900	207438	90382099
Completed suicide	57.21	12.22	164	38746	144894	90444643
Product dose omission issue	56.14	12.22	261	38649	291426	90298111
Discomfort	55.72	12.22	24	38886	274311	90315226
Diabetic ketoacidosis	55.21	12.22	60	38850	24347	90565190
Urinary tract infection	54.85	12.22	268	38642	305364	90284173
Hepatic enzyme increased	53.19	12.22	46	38864	360690	90228847
Product use issue	52.48	12.22	39	38871	329880	90259657
Musculoskeletal stiffness	51.24	12.22	32	38878	296500	90293037
Ischaemic cardiomyopathy	47.60	12.22	23	38887	2590	90586947
Diabetic neuropathy	45.74	12.22	27	38883	4547	90584990
Acute myocardial infarction	43.95	12.22	64	38846	34826	90554711
Death	42.99	12.22	339	38571	456212	90133325
Swelling	42.13	12.22	72	38838	418986	90170551
Thrombosis	41.52	12.22	95	38815	73156	90516381
Joint range of motion decreased	41.00	12.22	5	38905	135638	90453899
Impaired healing	40.83	12.22	25	38885	234174	90355363
Myocardial ischaemia	40.40	12.22	39	38871	13775	90575762
Psoriatic arthropathy	40.33	12.22	24	38886	228311	90361226
Chronic kidney disease	38.88	12.22	74	38836	50117	90539420
Chronic obstructive pulmonary disease	38.85	12.22	93	38817	73736	90515801
Cardiac disorder	38.21	12.22	79	38831	56793	90532744
Drug ineffective	37.65	12.22	397	38513	1383901	89205636
Alopecia	37.31	12.22	100	38810	494971	90094566
Bursitis	37.10	12.22	6	38904	131648	90457889
Asthenia	36.68	12.22	370	38540	533381	90056156
Cutaneous T-cell dyscrasia	36.48	12.22	8	38902	64	90589473
Pyrexia	36.39	12.22	153	38757	660332	89929205
Transient ischaemic attack	36.38	12.22	66	38844	43110	90546427
Fibromyalgia	35.98	12.22	22	38888	206247	90383290
Diarrhoea	35.22	12.22	582	38328	938608	89650929
Liver injury	34.49	12.22	15	38895	170552	90418985
Nausea	33.54	12.22	665	38245	1109651	89479886
Nodular rash	32.61	12.22	9	38901	199	90589338
Oedema peripheral	32.11	12.22	205	38705	257710	90331827
Atrial fibrillation	31.36	12.22	127	38783	133484	90456053
Pancreatitis acute	30.83	12.22	52	38858	32063	90557474
Gout	30.62	12.22	37	38873	16822	90572715
Weight decreased	30.36	12.22	272	38638	379638	90209899
Mobility decreased	30.14	12.22	38	38872	250696	90338841
Cellulitis	30.11	12.22	97	38813	91240	90498297
Hypoacusis	29.31	12.22	47	38863	27803	90561734
Grip strength decreased	29.01	12.22	3	38907	92573	90496964
Gastrointestinal haemorrhage	28.99	12.22	95	38815	90153	90499384
Ventricular hypertrophy	28.73	12.22	18	38892	3373	90586164
Inflammation	28.52	12.22	21	38889	178571	90410966
Therapeutic product effect decreased	28.51	12.22	47	38863	277524	90312013
Blister	28.27	12.22	41	38869	254957	90334580
Renal injury	28.24	12.22	28	38882	10215	90579322
Chest pain	28.22	12.22	234	38676	319411	90270126
Ill-defined disorder	27.93	12.22	23	38887	184868	90404669
Lung disorder	27.54	12.22	15	38895	149868	90439669
Stool analysis abnormal	27.36	12.22	6	38904	48	90589489
Toxicity to various agents	27.19	12.22	214	38696	287632	90301905
Stomatitis	26.85	12.22	48	38862	274650	90314887
Coronary artery occlusion	26.63	12.22	25	38885	8529	90581008
Rhabdomyolysis	26.35	12.22	64	38846	51192	90538345
Intentional product use issue	25.93	12.22	33	38877	216859	90372678
Condition aggravated	25.30	12.22	151	38759	595394	89994143
Acute coronary syndrome	25.19	12.22	27	38883	10786	90578751
Cardiovascular disorder	25.14	12.22	30	38880	13462	90576075
Fall	24.48	12.22	315	38595	481495	90108042
Plasma cell myeloma	24.30	12.22	54	38856	40774	90548763
Cardiac arrest	24.03	12.22	99	38811	104836	90484701
Hypersensitivity	23.98	12.22	107	38803	454570	90134967
Infection	23.74	12.22	78	38832	362016	90227521
Vision blurred	23.66	12.22	102	38808	110191	90479346
Acute respiratory failure	23.59	12.22	55	38855	42863	90546674
Emotional distress	23.55	12.22	50	38860	36612	90552925
Pernicious anaemia	23.41	12.22	10	38900	846	90588691
Gastrointestinal disorder	23.20	12.22	47	38863	256640	90332897
Wheezing	22.91	12.22	42	38868	238038	90351499
Product appearance confusion	22.70	12.22	6	38904	112	90589425
Epilepsy	22.60	12.22	4	38906	82202	90507335
Abdominal discomfort	22.45	12.22	117	38793	477211	90112326
Hyperlipidaemia	21.86	12.22	37	38873	22879	90566658
Hypercholesterolaemia	21.82	12.22	8	38902	100884	90488653
Sepsis	21.79	12.22	142	38768	179672	90409865
Hyperinsulinaemic hypoglycaemia	21.56	12.22	6	38904	137	90589400
International normalised ratio increased	21.12	12.22	56	38854	47260	90542277
Knee arthroplasty	20.90	12.22	5	38905	83177	90506360
Haemorrhage intracranial	20.84	12.22	29	38881	15133	90574404
Sleep disorder	20.83	12.22	33	38877	197997	90391540
Haemodialysis	20.65	12.22	22	38888	8725	90580812
Unevaluable event	20.63	12.22	61	38849	54787	90534750
Dilatation atrial	20.61	12.22	12	38898	1969	90587568
Angina unstable	20.57	12.22	20	38890	7123	90582414
Wound infection	20.51	12.22	10	38900	106392	90483145
Blood potassium increased	20.46	12.22	34	38876	20715	90568822
Hip arthroplasty	20.32	12.22	4	38906	76204	90513333
Ventricular dysfunction	20.16	12.22	15	38895	3716	90585821
Blood urea increased	20.14	12.22	42	38868	30371	90559166
Dizziness	20.13	12.22	360	38550	588924	90000613
Cardiomegaly	20.00	12.22	32	38878	18893	90570644
Injection site nodule	19.84	12.22	16	38894	4457	90585080
Drug-induced liver injury	19.81	12.22	7	38903	90311	90499226
Migraine	19.76	12.22	32	38878	190360	90399177
Hyperkalaemia	19.63	12.22	67	38843	64897	90524640
Flatulence	19.53	12.22	50	38860	41317	90548220
Hypervolaemia	19.13	12.22	43	38867	32714	90556823
Drug interaction	19.11	12.22	192	38718	276261	90313276
Treatment noncompliance	18.95	12.22	57	38853	51670	90537867
Therapeutic product effect incomplete	18.83	12.22	34	38876	193862	90395675
Fear	18.80	12.22	29	38881	16593	90572944
Essential hypertension	18.79	12.22	18	38892	6297	90583240
Autoimmune disorder	18.53	12.22	5	38905	76739	90512798
Respiratory failure	18.52	12.22	100	38810	118318	90471219
Nasopharyngitis	18.46	12.22	101	38809	407003	90182534
Blood creatinine increased	18.21	12.22	89	38821	101297	90488240
Pancreatic carcinoma	17.92	12.22	20	38890	8357	90581180
Product use in unapproved indication	17.79	12.22	79	38831	336157	90253380
Anhedonia	17.44	12.22	23	38887	11408	90578129
Adenocarcinoma pancreas	17.43	12.22	9	38901	1167	90588370
Suspected suicide	17.38	12.22	21	38889	9547	90579990
Haemoglobin decreased	17.30	12.22	124	38786	161832	90427705
Pancytopenia	17.11	12.22	99	38811	120164	90469373
Pregnancy	17.10	12.22	3	38907	62044	90527493
Renal disorder	17.09	12.22	45	38865	37814	90551723
Blood triglycerides increased	16.98	12.22	25	38885	13736	90575801
Hyperinsulinaemia	16.89	12.22	5	38905	143	90589394
Pulmonary hypertension	16.67	12.22	48	38862	42475	90547062
Peripheral vascular disorder	16.66	12.22	17	38893	6414	90583123
Arthralgia	16.59	12.22	235	38675	778287	89811250
Dysgeusia	16.58	12.22	55	38855	52505	90537032
Platelet count decreased	16.49	12.22	108	38802	136861	90452676
Glucose urine present	16.43	12.22	8	38902	916	90588621
Liver function test increased	16.31	12.22	8	38902	84847	90504690
Prescribed overdose	16.21	12.22	11	38899	97614	90491923
Night sweats	16.01	12.22	19	38891	128747	90460790
Peripheral venous disease	16.00	12.22	8	38902	83913	90505624
Pancreatitis haemorrhagic	15.85	12.22	7	38903	642	90588895
Arteriosclerosis coronary artery	15.71	12.22	20	38890	9583	90579954
Lipid metabolism disorder	15.66	12.22	5	38905	185	90589352
Coronary artery stenosis	15.65	12.22	15	38895	5251	90584286
White blood cell count decreased	15.63	12.22	124	38786	166985	90422552
Red blood cell sedimentation rate increased	15.56	12.22	8	38902	82587	90506950
Hypophagia	15.50	12.22	42	38868	35895	90553642
Visual acuity reduced	15.12	12.22	32	38878	23378	90566159
Diabetic retinopathy	14.91	12.22	11	38899	2691	90586846
Hepatitis	14.65	12.22	6	38904	70733	90518804
Blepharospasm	14.60	12.22	3	38907	55442	90534095
Dyspnoea	14.48	12.22	487	38423	880468	89709069
Colitis ulcerative	14.41	12.22	4	38906	60262	90529275
Anaemia	14.40	12.22	222	38688	352580	90236957
Foot deformity	14.19	12.22	4	38906	59647	90529890
Therapy non-responder	14.16	12.22	23	38887	136681	90452856
Laryngeal pain	13.91	12.22	13	38897	4409	90585128
Mitral valve incompetence	13.64	12.22	30	38880	22494	90567043
Hypoglycaemic seizure	13.54	12.22	6	38904	554	90588983
Leukopenia	13.46	12.22	14	38896	100696	90488841
Nephrolithiasis	13.43	12.22	49	38861	49036	90540501
Pulmonary fibrosis	13.22	12.22	16	38894	107487	90482050
Suicide attempt	13.20	12.22	8	38902	75391	90514146
Dialysis	13.15	12.22	20	38890	11309	90578228
Taste disorder	13.11	12.22	5	38905	61541	90527996
Prescribed underdose	13.07	12.22	8	38902	75011	90514526
Hunger	12.90	12.22	15	38895	6548	90582989
Incorrect route of product administration	12.80	12.22	3	38907	50623	90538914
Drug abuse	12.73	12.22	10	38900	82337	90507200
Catheterisation cardiac	12.66	12.22	13	38897	4943	90584594
Musculoskeletal pain	12.56	12.22	35	38875	171216	90418321
Gastritis	12.56	12.22	43	38867	41710	90547827
Sciatica	12.56	12.22	15	38895	101367	90488170
Angioedema	12.41	12.22	58	38852	64818	90524719
Necrobiosis lipoidica diabeticorum	12.36	12.22	3	38907	39	90589498
Body height decreased	12.35	12.22	20	38890	11929	90577608
Myalgia	12.27	12.22	122	38788	175003	90414534

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	833.78	11.90	584	40123	59270	42521358
Blood glucose increased	578.75	11.90	513	40194	73186	42507442
Cardiac failure congestive	342.31	11.90	415	40292	85187	42495441
Myocardial infarction	313.17	11.90	481	40226	123528	42457100
Completed suicide	222.29	11.90	359	40348	96106	42484522
Blood glucose decreased	216.93	11.90	147	40560	14072	42566556
Coronary artery disease	202.49	11.90	253	40454	53467	42527161
Off label use	138.41	11.90	250	40457	638085	41942543
Glycosylated haemoglobin increased	99.24	11.90	89	40618	12835	42567793
Cerebrovascular accident	98.95	11.90	258	40449	96902	42483726
Pancreatitis	75.97	11.90	143	40564	43125	42537503
Drug abuse	69.49	11.90	9	40698	104762	42475866
Diabetes mellitus inadequate control	65.26	11.90	77	40630	15313	42565315
Product complaint	64.24	11.90	50	40657	5927	42574701
Febrile neutropenia	62.99	11.90	51	40656	185652	42394976
Product use in unapproved indication	57.33	11.90	55	40652	184401	42396227
Mental status changes	55.91	11.90	124	40583	41991	42538637
Myocardial ischaemia	53.48	11.90	75	40632	17687	42562941
Injury	51.20	11.90	83	40624	22233	42558395
Blood glucose abnormal	51.06	11.90	47	40660	7006	42573622
General physical health deterioration	49.47	11.90	43	40664	151203	42429425
Ischaemic cardiomyopathy	46.32	11.90	43	40664	6479	42574149
Product residue present	44.81	11.90	30	40677	2811	42577817
Cardiac disorder	43.81	11.90	124	40583	48808	42531820
Diabetic neuropathy	42.70	11.90	35	40672	4467	42576161
Neutropenia	37.84	11.90	84	40623	199347	42381281
C-reactive protein increased	36.53	11.90	8	40699	63552	42517076
Drug ineffective	36.52	11.90	406	40301	629791	41950837
Cardiovascular disorder	35.24	11.90	53	40654	13312	42567316
Blood glucose fluctuation	34.05	11.90	31	40676	4556	42576072
Diabetic ketoacidosis	33.29	11.90	69	40638	22298	42558330
Myasthenic syndrome	33.04	11.90	16	40691	805	42579823
Interstitial lung disease	32.76	11.90	17	40690	78445	42502183
Spur cell anaemia	31.06	11.90	8	40699	56	42580572
Hypophagia	30.97	11.90	75	40632	26881	42553747
Asthenia	30.78	11.90	406	40301	280387	42300241
Acute myocardial infarction	30.38	11.90	123	40584	58042	42522586
Autoimmune myocarditis	30.35	11.90	11	40696	264	42580364
Pyrexia	29.99	11.90	237	40470	393805	42186823
Emotional distress	29.24	11.90	54	40653	16039	42564589
Lactic acidosis	28.84	11.90	102	40605	45159	42535469
Type 2 diabetes mellitus	28.69	11.90	58	40649	18413	42562215
Pancreatitis acute	27.10	11.90	82	40625	33482	42547146
Angina unstable	26.83	11.90	43	40664	11405	42569223
Unresponsive to stimuli	25.62	11.90	77	40630	31326	42549302
Myelosuppression	25.59	11.90	4	40703	40457	42540171
Glycosylated haemoglobin abnormal	25.56	11.90	10	40697	298	42580330
Condition aggravated	24.15	11.90	148	40559	260606	42320022
Treatment failure	22.74	11.90	16	40691	62608	42518020
Transient ischaemic attack	22.32	11.90	77	40630	33662	42546966
Diabetes mellitus	21.67	11.90	114	40593	59973	42520655
Hyperglycaemia	21.62	11.90	94	40613	45765	42534863
Bladder cancer	21.28	11.90	49	40658	16998	42563630
Product dose omission issue	21.16	11.90	233	40474	154132	42426496
Anhedonia	21.15	11.90	31	40676	7609	42573019
Renal injury	20.81	11.90	40	40667	12240	42568388
Drug resistance	20.31	11.90	4	40703	34244	42546384
Leukopenia	20.18	11.90	25	40682	74721	42505907
Peripheral vascular disorder	19.93	11.90	25	40682	5292	42575336
Agranulocytosis	19.42	11.90	3	40704	30609	42550019
Renal failure	19.27	11.90	216	40491	143510	42437118
Chest pain	18.84	11.90	210	40497	139320	42441308
Product quality issue	18.69	11.90	48	40659	17834	42562794
Drug intolerance	18.63	11.90	30	40677	80394	42500234
Arteriosclerosis	18.51	11.90	48	40659	17941	42562687
Gastrointestinal mucosal necrosis	18.50	11.90	7	40700	190	42580438
International normalised ratio increased	18.49	11.90	93	40614	48075	42532553
Weight decreased	18.49	11.90	290	40417	207658	42372970
Fatigue	18.12	11.90	544	40163	435097	42145531
Cytokine release syndrome	18.07	11.90	10	40697	44517	42536111
Poor quality product administered	17.92	11.90	16	40691	2292	42578336
Interstitial granulomatous dermatitis	17.85	11.90	7	40700	210	42580418
Dizziness	17.62	11.90	335	40372	248919	42331709
Cardiomyopathy	17.49	11.90	49	40658	19161	42561467
Mucosal inflammation	17.42	11.90	13	40694	49361	42531267
Intentional product use issue	17.40	11.90	26	40681	71807	42508821
Lower respiratory tract infection	17.09	11.90	9	40698	41197	42539431
Distributive shock	16.85	11.90	16	40691	2480	42578148
Acute kidney injury	16.71	11.90	464	40243	366873	42213755
Drug ineffective for unapproved indication	16.49	11.90	12	40695	46151	42534477
Pancreatic carcinoma	16.15	11.90	31	40676	9475	42571153
Therapeutic product effect incomplete	15.93	11.90	27	40680	70912	42509716
Diverticulum	15.89	11.90	27	40680	7514	42573114
Glycosylated haemoglobin decreased	15.87	11.90	8	40699	439	42580189
Product use issue	15.65	11.90	31	40676	76720	42503908
Coronary artery occlusion	15.29	11.90	33	40674	10964	42569664
Cytomegalovirus infection	15.04	11.90	6	40701	32300	42548328
Eczema	14.80	11.90	7	40700	34079	42546549
COVID-19	14.62	11.90	59	40648	115889	42464739
Neutrophil count decreased	14.37	11.90	24	40683	63391	42517237
Altered state of consciousness	14.35	11.90	5	40702	29254	42551374
Vision blurred	14.26	11.90	94	40613	53605	42527023
Thrombocytopenia	14.16	11.90	115	40592	190164	42390464
Suicide attempt	14.00	11.90	14	40693	46086	42534542
Chronic kidney disease	13.97	11.90	85	40622	47156	42533472
Fall	13.86	11.90	307	40400	234213	42346415
Electrocardiogram ST-T change	13.64	11.90	8	40699	594	42580034
Acute coronary syndrome	13.62	11.90	38	40669	14827	42565801
Anaphylactic shock	13.43	11.90	3	40704	23514	42557114
Blood loss anaemia	13.29	11.90	29	40678	9707	42570921
Hyperkalaemia	13.18	11.90	126	40581	80332	42500296
Fear	13.12	11.90	31	40676	10934	42569694
Tachycardia	13.02	11.90	51	40656	101036	42479592
Occult blood positive	12.85	11.90	18	40689	4239	42576389
Suspected suicide	12.80	11.90	22	40685	6177	42574451
Dehydration	12.70	11.90	198	40509	141569	42439059
Arteriosclerosis coronary artery	12.68	11.90	43	40664	18634	42561994
Renal disorder	12.60	11.90	58	40649	28922	42551706
Blood pressure fluctuation	12.52	11.90	5	40702	26903	42553725
Multiple injuries	12.47	11.90	12	40695	1890	42578738
Cholestasis	12.47	11.90	8	40699	32871	42547757
Hyphaema	12.32	11.90	8	40699	712	42579916
Pancreatic carcinoma metastatic	12.05	11.90	15	40692	3151	42577477
Infusion related reaction	12.02	11.90	25	40682	60781	42519847
Blood creatinine increased	11.98	11.90	159	40548	109844	42470784
Human anaplasmosis	11.96	11.90	4	40703	75	42580553
Cellulitis	11.91	11.90	100	40607	61485	42519143

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	1428.53	11.88	860	61253	115244	110411942
Blood glucose increased	964.62	11.88	708	61405	131788	110395398
Cardiac failure congestive	627.71	11.88	583	61530	150417	110376769
Myocardial infarction	588.28	11.88	628	61485	191455	110335731
Blood glucose decreased	421.29	11.88	241	61872	29247	110497939
Coronary artery disease	388.37	11.88	322	61791	71368	110455818
Completed suicide	348.48	11.88	545	61568	241836	110285350
Cerebrovascular accident	244.37	11.88	396	61717	180888	110346298
Lactic acidosis	171.28	11.88	235	61878	92576	110434610
Glycosylated haemoglobin increased	166.52	11.88	124	61989	23495	110503691
Off label use	158.54	11.88	384	61729	1499801	109027385
Diabetes mellitus inadequate control	129.36	11.88	118	61995	29657	110497529
Product residue present	123.94	11.88	55	62058	3886	110523300
Mental status changes	120.22	11.88	179	61934	75943	110451243
Infusion related reaction	114.16	11.88	36	62077	381126	110146060
Synovitis	111.49	11.88	12	62101	274080	110253106
Drug intolerance	108.89	11.88	46	62067	406466	110120720
Hand deformity	108.71	11.88	3	62110	218503	110308683
Acute kidney injury	103.41	11.88	660	61453	634770	109892416
General physical health deterioration	103.37	11.88	55	62058	425240	110101946
Pancreatitis	99.32	11.88	184	61929	93349	110433837
Ischaemic cardiomyopathy	97.37	11.88	59	62054	7952	110519234
Contraindicated product administered	95.72	11.88	13	62100	248254	110278932
Acute myocardial infarction	95.54	11.88	170	61943	83607	110443579
Product complaint	95.47	11.88	72	62041	13900	110513286
Systemic lupus erythematosus	91.95	11.88	16	62097	254322	110272864
Lower respiratory tract infection	90.78	11.88	14	62099	243092	110284094
Death	90.77	11.88	687	61426	698182	109829004
Pericarditis	90.63	11.88	9	62104	219105	110308081
Myocardial ischaemia	88.17	11.88	91	62022	26593	110500593
C-reactive protein increased	84.99	11.88	11	62102	217908	110309278
Rheumatoid arthritis	84.99	11.88	31	62082	299582	110227604
Cardiac disorder	82.16	11.88	151	61962	76129	110451057
Helicobacter infection	82.14	11.88	5	62108	181872	110345314
Blood glucose abnormal	80.46	11.88	63	62050	12853	110514333
Hyperglycaemia	80.02	11.88	159	61954	84931	110442255
Drug ineffective	79.48	11.88	515	61598	1520025	109007161
Renal failure	78.83	11.88	293	61820	226281	110300905
Diabetic ketoacidosis	78.32	11.88	107	62006	41951	110485235
Glossodynia	78.02	11.88	15	62098	221989	110305197
Treatment failure	76.43	11.88	30	62083	277204	110249982
Hypoglycaemic coma	75.74	11.88	44	62069	5489	110521697
Euglycaemic diabetic ketoacidosis	75.24	11.88	58	62055	11565	110515621
Blood glucose fluctuation	71.88	11.88	48	62065	7650	110519536
Diabetic neuropathy	71.09	11.88	46	62067	6953	110520233
Arthropathy	70.09	11.88	37	62076	287485	110239701
Irritable bowel syndrome	67.24	11.88	7	62106	164208	110362978
Product use in unapproved indication	64.07	11.88	95	62018	447282	110079904
Dehydration	63.67	11.88	318	61795	279193	110247993
Product dose omission issue	62.29	11.88	350	61763	321432	110205754
Cardiovascular disorder	61.84	11.88	70	62043	22690	110504496
Diabetes mellitus	59.20	11.88	155	61958	99226	110427960
Musculoskeletal stiffness	58.54	11.88	43	62070	279779	110247407
Wound	57.38	11.88	30	62083	234407	110292779
Fibromyalgia	57.06	11.88	13	62100	170896	110356290
Transient ischaemic attack	55.92	11.88	116	61997	63866	110463320
Drug abuse	54.44	11.88	16	62097	177395	110349791
Angina unstable	54.21	11.88	56	62057	16376	110510810
Asthenia	53.62	11.88	607	61506	688392	109838794
Inflammation	53.10	11.88	21	62092	193217	110333969
Joint swelling	52.48	11.88	106	62007	442739	110084447
Hypophagia	51.48	11.88	100	62013	52526	110474660
Product use issue	50.92	11.88	60	62053	311635	110215551
Rhabdomyolysis	48.99	11.88	164	61949	120237	110406949
International normalised ratio increased	48.32	11.88	132	61981	86640	110440546
Hyperkalaemia	47.52	11.88	176	61937	135620	110391566
Psoriatic arthropathy	46.95	11.88	26	62087	196735	110330451
Pyrexia	46.84	11.88	304	61809	897961	109629225
Chronic obstructive pulmonary disease	46.48	11.88	151	61962	109007	110418179
Impaired healing	45.50	11.88	27	62086	196690	110330496
Atrial fibrillation	45.22	11.88	251	61862	229391	110297795
Alopecia	45.21	11.88	85	62028	364668	110162518
Gastrointestinal haemorrhage	44.75	11.88	198	61915	165320	110361866
Pancreatitis acute	44.39	11.88	102	62011	60172	110467014
Bursitis	43.13	11.88	10	62103	129908	110397278
Unresponsive to stimuli	42.69	11.88	104	62009	63686	110463500
Coronary artery occlusion	41.98	11.88	48	62065	15724	110511462
Lip dry	41.66	11.88	4	62109	100079	110427107
Intentional product use issue	41.26	11.88	47	62066	247859	110279327
Lung disorder	41.23	11.88	25	62088	180022	110347164
Emotional distress	41.19	11.88	83	62030	44764	110482422
Chest pain	41.11	11.88	356	61757	376019	110151167
Ill-defined disorder	39.99	11.88	19	62094	156834	110370352
Bladder cancer	39.87	11.88	53	62060	20239	110506947
Epilepsy	39.20	11.88	5	62108	100204	110426982
Acute coronary syndrome	38.86	11.88	56	62057	23056	110504130
Renal injury	38.51	11.88	50	62063	18663	110508523
Hepatic enzyme increased	37.83	11.88	77	62036	320815	110206371
Infection	37.74	11.88	93	62020	362107	110165079
Discomfort	37.62	11.88	39	62074	214668	110312518
Febrile neutropenia	37.36	11.88	76	62037	316691	110210495
Peripheral vascular disorder	37.27	11.88	34	62079	8542	110518644
Therapeutic product effect decreased	36.80	11.88	50	62063	244266	110282920
Condition aggravated	36.61	11.88	252	61861	734584	109792602
Cellulitis	36.56	11.88	154	61959	125862	110401324
Gastrointestinal disorder	35.96	11.88	50	62063	241902	110285284
Hypoacusis	35.80	11.88	68	62045	35123	110492063
Suspected suicide	35.07	11.88	43	62070	15156	110512030
Sleep disorder	34.90	11.88	36	62077	198608	110328578
Cutaneous T-cell dyscrasia	34.56	11.88	8	62105	62	110527124
Myasthenic syndrome	34.41	11.88	16	62097	1260	110525926
Myelosuppression	33.94	11.88	6	62107	94334	110432852
Treatment noncompliance	33.85	11.88	104	62009	72886	110454300
Chronic kidney disease	33.80	11.88	107	62006	76184	110451002
Cardiac arrest	32.88	11.88	206	61907	196547	110330639
Joint range of motion decreased	32.24	11.88	14	62099	121818	110405368
Arteriosclerosis	31.82	11.88	53	62060	24714	110502472
Urinary tract infection	31.73	11.88	301	61812	325981	110201205
Stomatitis	31.72	11.88	65	62048	270177	110257009
Liver injury	31.59	11.88	23	62090	150390	110376796
Therapeutic product effect incomplete	31.54	11.88	48	62065	223757	110303429
Blood creatinine increased	31.51	11.88	193	61920	182696	110344490
Mobility decreased	31.50	11.88	53	62060	237369	110289817
Arteriosclerosis coronary artery	29.96	11.88	52	62061	25066	110502120
Anhedonia	29.86	11.88	40	62073	15388	110511798
Spur cell anaemia	29.41	11.88	8	62105	126	110527060
Migraine	29.15	11.88	32	62081	171620	110355566
Blister	29.03	11.88	52	62061	227324	110299862
Plasma cell myeloma	28.55	11.88	89	62024	62847	110464339
Fall	27.90	11.88	485	61628	602997	109924189
Drug reaction with eosinophilia and systemic symptoms	27.89	11.88	6	62107	82089	110445097
Oedema peripheral	27.06	11.88	293	61820	328367	110198819
Haemodialysis	27.01	11.88	41	62072	17678	110509508
Hypersensitivity	26.87	11.88	126	61987	403872	110123314
Autoimmune myocarditis	26.81	11.88	11	62102	640	110526546
Arthralgia	26.53	11.88	295	61818	779337	109747849
Essential hypertension	26.35	11.88	27	62086	7820	110519366
Glycosylated haemoglobin abnormal	26.32	11.88	10	62103	474	110526712
Autoimmune disorder	26.27	11.88	3	62110	65480	110461706
Cardiomyopathy	26.09	11.88	58	62055	33467	110493719
Nodular rash	25.97	11.88	9	62104	327	110526859
Occult blood positive	25.70	11.88	26	62087	7419	110519767
Wheezing	25.44	11.88	67	62046	255163	110272023
Angioedema	25.24	11.88	116	61997	98384	110428802
Mitral valve incompetence	25.20	11.88	57	62056	33272	110493914
Myopathy	25.11	11.88	48	62065	24912	110502274
Fear	25.07	11.88	46	62067	23147	110504039
Peripheral venous disease	25.05	11.88	8	62105	84109	110443077
Dizziness	24.77	11.88	539	61574	697654	109829532
Frequent bowel movements	24.70	11.88	5	62108	71385	110455801
Weight decreased	24.51	11.88	384	61729	467673	110059513
Thrombosis	24.26	11.88	123	61990	108539	110418647
Wound infection	24.11	11.88	12	62101	96453	110430733
Swelling	23.62	11.88	109	62004	350932	110176254
Vision blurred	23.39	11.88	138	61975	128884	110398302
Poor quality product administered	23.36	11.88	20	62093	4621	110522565
Musculoskeletal pain	23.23	11.88	42	62071	182981	110344205
Sinusitis	23.15	11.88	87	62026	296601	110230585
Nasopharyngitis	22.83	11.88	129	61984	394232	110132954
Stool analysis abnormal	22.65	11.88	7	62106	176	110527010
Unevaluable event	22.61	11.88	79	62034	59148	110468038
Dialysis	22.60	11.88	40	62073	19579	110507607
Liver disorder	22.56	11.88	28	62085	142215	110384971
Blood pressure fluctuation	22.49	11.88	7	62106	74817	110452369
Toxicity to various agents	22.11	11.88	386	61727	480169	110047017
Blood potassium increased	22.02	11.88	54	62059	33195	110493991
Drug-induced liver injury	21.95	11.88	21	62092	120046	110407140
Gamma-glutamyltransferase increased	21.83	11.88	4	62109	61305	110465881
Interstitial lung disease	21.50	11.88	28	62085	139306	110387880
Ventricular hypertrophy	21.44	11.88	23	62090	7022	110520164
Blood loss anaemia	21.08	11.88	37	62076	17988	110509198
Haemoglobin decreased	21.05	11.88	223	61890	248504	110278682
Gastrointestinal mucosal necrosis	20.84	11.88	7	62106	231	110526955
Blepharospasm	20.83	11.88	3	62110	54848	110472338
Toe amputation	20.44	11.88	18	62095	4320	110522866
Hyperlipidaemia	20.41	11.88	55	62058	35793	110491393
Colitis ulcerative	20.29	11.88	9	62104	77354	110449832
Dilatation atrial	20.21	11.88	17	62096	3835	110523351
Agranulocytosis	20.01	11.88	5	62108	61755	110465431
Gout	19.73	11.88	55	62058	36511	110490675
Hyperinsulinaemic hypoglycaemia	19.44	11.88	7	62106	285	110526901
Drug resistance	19.39	11.88	4	62109	56370	110470816
Interstitial granulomatous dermatitis	19.39	11.88	7	62106	287	110526899
Diabetic retinopathy	19.26	11.88	16	62097	3548	110523638
Hypervolaemia	18.91	11.88	66	62047	49394	110477792
Syncope	18.76	11.88	185	61928	202351	110324835
Osteoporosis	18.72	11.88	13	62100	87139	110440047
Pernicious anaemia	18.71	11.88	9	62104	765	110526421
Coronary artery stenosis	18.43	11.88	30	62083	13728	110513458
Neutropenia	18.35	11.88	129	61984	374491	110152695
Taste disorder	18.13	11.88	7	62106	65380	110461806
Leukopenia	18.13	11.88	35	62078	148756	110378430
Prescribed underdose	18.03	11.88	7	62106	65167	110462019
Product solubility abnormal	17.95	11.88	10	62103	1152	110526034
Asthma	17.87	11.88	76	62037	250215	110276971
Incorrect route of product administration	17.53	11.88	7	62106	64054	110463132
Therapy non-responder	17.48	11.88	39	62074	157268	110369918
Acute respiratory failure	17.37	11.88	86	62027	75174	110452012
Hip arthroplasty	17.18	11.88	5	62108	55808	110471378
Loss of consciousness	17.07	11.88	177	61936	196129	110331057
Multiple injuries	17.03	11.88	15	62098	3599	110523587
Right ventricular failure	17.03	11.88	42	62071	25912	110501274
Cardiomegaly	16.90	11.88	45	62068	29085	110498101
Suicide attempt	16.76	11.88	20	62093	103374	110423812
Cytomegalovirus infection	16.53	11.88	5	62108	54439	110472747
Carotid artery stenosis	16.39	11.88	23	62090	9240	110517946
Cognitive disorder	16.36	11.88	15	62098	87496	110439690
Product physical issue	16.32	11.88	17	62096	5019	110522167
Obesity	16.26	11.88	24	62089	113327	110413859
High density lipoprotein decreased	16.20	11.88	18	62095	5715	110521471
Cholestasis	16.16	11.88	8	62105	64510	110462676
Nausea	16.13	11.88	848	61265	1234842	109292344
Glucose urine present	16.09	11.88	12	62101	2277	110524909
Haemorrhage intracranial	16.05	11.88	44	62069	28925	110498261
Osteoarthritis	15.96	11.88	51	62062	182572	110344614
Hyperinsulinaemia	15.86	11.88	6	62107	281	110526905
Cytokine release syndrome	15.76	11.88	10	62103	70296	110456890
Hyphaema	15.67	11.88	9	62104	1098	110526088
Laryngeal pain	15.59	11.88	18	62095	5957	110521229
Cardio-respiratory arrest	15.59	11.88	115	61998	115721	110411465
Haematocrit decreased	15.58	11.88	76	62037	66041	110461145
Abdominal discomfort	15.44	11.88	144	61969	393714	110133472
Eczema	15.25	11.88	11	62102	72282	110454904
Lower limb fracture	15.20	11.88	12	62101	75336	110451850
Anaphylactic shock	15.18	11.88	5	62108	51541	110475645
Full blood count decreased	15.12	11.88	46	62067	32053	110495133
Deep vein thrombosis	15.08	11.88	132	61981	139755	110387431
Blood urea increased	15.04	11.88	66	62047	54891	110472295
Tricuspid valve incompetence	15.00	11.88	38	62075	23835	110503351
Angina pectoris	14.96	11.88	72	62041	62223	110464963
Electrocardiogram ST-T change	14.94	11.88	10	62103	1600	110525586
Sciatica	14.85	11.88	18	62095	92381	110434805
Nail disorder	14.79	11.88	7	62106	57928	110469258
Renal disorder	14.76	11.88	61	62052	49418	110477768
Drug ineffective for unapproved indication	14.53	11.88	22	62091	102816	110424370
Diarrhoea	14.46	11.88	780	61333	1138725	109388461
Pulmonary fibrosis	14.26	11.88	22	62091	102020	110425166
Night sweats	14.25	11.88	34	62079	133949	110393237
Dyspnoea	14.11	11.88	758	61355	1106114	109421072
Distributive shock	14.10	11.88	17	62096	5887	110521299
Fluid retention	14.07	11.88	96	62017	94211	110432975
Hypoglycaemic seizure	14.02	11.88	8	62105	964	110526222
Red blood cell sedimentation rate increased	13.96	11.88	14	62099	78288	110448898
Respiratory failure	13.77	11.88	183	61930	215149	110312037
Dysgeusia	13.43	11.88	76	62037	69909	110457277
Acidosis	13.27	11.88	35	62078	22496	110504690
Lethargy	13.22	11.88	94	62019	93482	110433704
Human anaplasmosis	13.12	11.88	4	62109	96	110527090
Pancreatic carcinoma	13.03	11.88	27	62086	14845	110512341
Inadequate analgesia	12.76	11.88	15	62098	5062	110522124
Sinus tachycardia	12.61	11.88	54	62059	44439	110482747
Product appearance confusion	12.43	11.88	4	62109	115	110527071
Ventricular dysfunction	12.34	11.88	18	62095	7493	110519693
Knee arthroplasty	12.30	11.88	11	62102	64937	110462249
Hypercholesterolaemia	12.30	11.88	20	62093	90817	110436369
Delirium	12.30	11.88	37	62076	134988	110392198
Ketoacidosis	12.18	11.88	21	62092	10066	110517120
Wrong product administered	12.18	11.88	22	62091	10938	110516248
Foot deformity	12.16	11.88	6	62107	48474	110478712
Prescribed overdose	12.12	11.88	19	62094	87562	110439624
Glycosylated haemoglobin decreased	12.11	11.88	7	62106	865	110526321
Hepatitis	12.03	11.88	20	62093	90034	110437152
Blood sodium decreased	12.03	11.88	48	62065	38271	110488915
Mitral valve calcification	12.02	11.88	9	62104	1719	110525467
Pulmonary hypertension	11.97	11.88	62	62051	55158	110472028
Blood triglycerides increased	11.95	11.88	35	62078	23891	110503295
Adenocarcinoma pancreas	11.90	11.88	10	62103	2253	110524933

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BB07	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas
FDA CS	M0020795	Sulfonylurea Compounds
MeSH PA	D007004	Hypoglycemic Agents
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:77194	EC 2.7.1.33 (pantothenate kinase) inhibitor
CHEBI has role	CHEBI:90415	insulin secretagogue
CHEBI has role	CHEBI:145947	antiatherosclerotic agent
FDA EPC	N0000175608	Sulfonylurea

Related Drugs by ATC class:

A10BB Sulfonylureas 12 drugs

acetohexamidecarbutamidechlorpropamideglibenclamideglibornuridegliclazideglimepiridegliquidoneglisoxepidemetahexamidetolazamidetolbutamide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Acute vomiting	contraindication	23971007
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Dehydration	contraindication	34095006
Infectious disease	contraindication	40733004
Hepatic porphyria	contraindication	55056006	DOID:3133
Ketoacidosis	contraindication	56051008
Metabolic acidosis	contraindication	59455009
Hemolytic anemia	contraindication	61261009	DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia	contraindication	62403005
Hypopituitarism	contraindication	74728003	DOID:9406
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Cobalamin deficiency	contraindication	190634004
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Sepsis syndrome	contraindication	238150007
Primary adrenocortical insufficiency	contraindication	373662000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Severe diarrhea	contraindication	409587002
Traumatic injury	contraindication	417746004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Prolonged-Severe Nausea and Vomiting	contraindication
Radiography with IV Iodinated Contrast Agent	contraindication
Severe Hypoxemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.31	acidic
pKa2	11.71	acidic
pKa3	12.9	acidic
pKa4	3.19	Basic
pKa5	0.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sulfonylurea receptor 1, Kir6.2	Ion channel	Q09428 Q14654	ABCC8_HUMAN KCJ11_HUMAN	BLOCKER	Kd	9.10		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
4018508	VUID
N0000146830	NUI
D00335	KEGG_DRUG
4018508	VANDF
C0017642	UMLSCUI
CHEBI:5384	CHEBI
CHEMBL1073	ChEMBL_ID
D005913	MESH_DESCRIPTOR_UI
DB01067	DRUGBANK_ID
6821	IUPHAR_LIGAND_ID
3090	INN_ID
X7WDT95N5C	UNII
3478	PUBCHEM_CID
151822	RXNORM
4783	MMSL
574	MMSL
595	MMSL
d00246	MMSL
000913	NDDF
26124005	SNOMEDCT_US
387143009	SNOMEDCT_US
X7WDT95N5C	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
GlucotrolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0170	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	27 sections
GlucotrolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0174	TABLET, EXTENDED RELEASE	5 mg	ORAL	NDA	27 sections
GlucotrolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0178	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7455	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	27 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7456	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	27 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7457	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0460	TABLET	5 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0461	TABLET	10 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8407	TABLET	5 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8408	TABLET	10 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6637	TABLET	5 mg	ORAL	ANDA	20 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-192	TABLET	10 mg	ORAL	ANDA	12 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-193	TABLET	5 mg	ORAL	ANDA	12 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-220	TABLET	5 mg	ORAL	ANDA	20 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-221	TABLET	10 mg	ORAL	ANDA	20 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	12634-729	TABLET	5 mg	ORAL	ANDA	26 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	12634-790	TABLET	10 mg	ORAL	ANDA	26 sections
GLIPIZIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-286	TABLET	5 mg	ORAL	ANDA	12 sections
GLIPIZIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-287	TABLET	10 mg	ORAL	ANDA	12 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-894	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-895	TABLET, EXTENDED RELEASE	5 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-896	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-469	TABLET	5 mg	ORAL	ANDA	12 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-470	TABLET	10 mg	ORAL	ANDA	12 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	21695-894	TABLET, FILM COATED	5 mg	ORAL	ANDA	29 sections
GlipizideER	HUMAN PRESCRIPTION DRUG LABEL	1	21695-967	TABLET, FILM COATED, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	23 sections
Glipizide and Metformin HCl	HUMAN PRESCRIPTION DRUG LABEL	2	23155-115	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	14 sections
Glipizide and Metformin HCl	HUMAN PRESCRIPTION DRUG LABEL	2	23155-115	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	14 sections
Glipizide and Metformin HCl	HUMAN PRESCRIPTION DRUG LABEL	2	23155-116	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	14 sections
Glipizide and Metformin HCl	HUMAN PRESCRIPTION DRUG LABEL	2	23155-116	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	14 sections